Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sumitomo Pharma Co., Ltd. (4506.T)
Osaka, JP
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.59% | +4.60% | -16.14% | -30.92% | -28.90% | -30.66% | +96.83% | +112.25% | -13.02% | +14.61% | +207.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 3 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+13.7% ★ Q1'26: -0.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+352.2% ★ Q1'26: -133.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.3% ★ Q1'26: +27.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.1% Q1'26: -4.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.8% ★ Q1'26: -2.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.05× Q1'26: 610.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 7 EPS Ana. |
Mar 2027 7 Rev. Ana. 7 EPS Ana. |
Mar 2028 6 Rev. Ana. 6 EPS Ana. |
Mar 2029 3 Rev. Ana. 3 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
371.37B
est: 370.71B (+0.2%)
|
403.21B
est: 400.87B (+0.6%)
|
408.36B
est: 405.25B (+0.8%)
|
466.84B
est: 479.89B (-2.7%)
|
459.27B
est: 461.15B (-0.4%)
|
482.73B
est: 477.39B (+1.1%)
|
515.95B
est: 519.51B (-0.7%)
|
560.04B
est: 554.44B (+1.0%)
|
555.54B
est: 557.45B (-0.3%)
|
314.56B
est: 329.55B (-4.5%)
|
398.83B
est: 372.55B (+7.1%)
|
446.16B
413.57B – 469.28B
+19.8% YoY
|
509.04B
472.66B – 573.05B
+14.1% YoY
|
557.90B
473.24B – 660.87B
+9.6% YoY
|
567.07B
557.54B – 576.60B
+1.6% YoY
|
573.42B
508.58B – 663.00B
+1.1% YoY
|
| EBITDA |
42.50B
est: -24.90B (+270.7%)
|
57.19B
est: -26.93B (+312.4%)
|
73.69B
est: -27.22B (+370.7%)
|
92.53B
est: -32.23B (+387.1%)
|
71.18B
est: -30.97B (+329.8%)
|
68.45B
est: -32.07B (+313.5%)
|
91.05B
est: -34.89B (+360.9%)
|
94.90B
est: -37.24B (+354.8%)
|
52.47B
est: -37.44B (+240.1%)
|
36.29B
est: 44.56B (-18.6%)
|
47.98B
est: 50.37B (-4.7%)
|
60.33B
55.92B – 63.45B
+19.8% YoY
|
68.83B
63.91B – 77.48B
+14.1% YoY
|
75.43B
63.99B – 89.36B
+9.6% YoY
|
76.67B
75.39B – 77.96B
+1.6% YoY
|
77.53B
68.76B – 89.65B
+1.1% YoY
|
| EBIT |
23.28B
est: -51.39B (+145.3%)
|
36.93B
est: -55.57B (+166.5%)
|
60.97B
est: -56.17B (+208.5%)
|
79.64B
est: -66.52B (+219.7%)
|
57.21B
est: -63.92B (+189.5%)
|
51.08B
est: -66.17B (+177.2%)
|
68.38B
est: -72.01B (+195.0%)
|
56.55B
est: -76.85B (+173.6%)
|
11.20B
est: -77.27B (+114.5%)
|
-1.48B
est: 20.12B (-107.3%)
|
22.42B
est: 22.74B (-1.4%)
|
27.23B
25.25B – 28.65B
+19.8% YoY
|
31.07B
28.85B – 34.98B
+14.1% YoY
|
34.06B
28.89B – 40.34B
+9.6% YoY
|
34.62B
34.03B – 35.20B
+1.6% YoY
|
35.00B
31.04B – 40.47B
+1.1% YoY
|
| Net Income |
15.45B
est: 15.28B (+1.1%)
|
24.70B
est: 22.54B (+9.6%)
|
31.32B
est: 28.33B (+10.5%)
|
53.45B
est: 54.53B (-2.0%)
|
48.63B
est: 41.15B (+18.2%)
|
40.75B
est: 34.19B (+19.2%)
|
56.22B
est: 29.40B (+91.2%)
|
56.41B
est: 41.76B (+35.1%)
|
-74.51B
est: -47.41B (-57.2%)
|
-314.97B
est: -260.17B (-21.1%)
|
23.63B
est: 18.90B (+25.0%)
|
99.30B
75.46B – 120.43B
+425.3% YoY
|
85.79B
59.26B – 114.35B
-13.6% YoY
|
83.02B
39.17B – 112.49B
-3.2% YoY
|
71.93B
51.45B – 117.71B
-13.4% YoY
|
96.14B
82.01B – 115.67B
+33.7% YoY
|
| SGA |
170.44B
est: 233.82B (-27.1%)
|
174.05B
est: 252.84B (-31.2%)
|
172.34B
est: 255.60B (-32.6%)
|
177.11B
est: 302.68B (-41.5%)
|
172.58B
est: 290.86B (-40.7%)
|
143.08B
est: 301.10B (-52.5%)
|
173.67B
est: 327.67B (-47.0%)
|
217.34B
est: 349.70B (-37.9%)
|
339.21B
est: 351.60B (-3.5%)
|
397.71B
est: 197.84B (+101.0%)
|
160.39B
est: 223.66B (-28.3%)
|
267.85B
248.28B – 281.73B
+19.8% YoY
|
305.60B
283.76B – 344.03B
+14.1% YoY
|
334.93B
284.11B – 396.75B
+9.6% YoY
|
340.44B
334.72B – 346.16B
+1.6% YoY
|
344.25B
305.32B – 398.03B
+1.1% YoY
|
| EPS |
38.88
est: 38.47 (+1.1%)
|
62.16
est: 56.72 (+9.6%)
|
78.82
est: 71.31 (+10.5%)
|
134.53
est: 137.26 (-2.0%)
|
122.39
est: 103.58 (+18.2%)
|
102.58
est: 86.05 (+19.2%)
|
141.50
est: 74.01 (+91.2%)
|
141.99
est: 105.11 (+35.1%)
|
-187.55
est: -119.34 (-57.2%)
|
-792.79
est: -654.85 (-21.1%)
|
59.49
est: 51.09 (+16.4%)
|
261.32
189.94 – 303.14
+411.5% YoY
|
213.21
149.16 – 287.82
-18.4% YoY
|
212.42
98.61 – 283.15
-0.4% YoY
|
217.69
129.51 – 296.29
+2.5% YoY
|
242.00
206.42 – 291.15
+11.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Equity Factor ETF INTF | 0.16% | 5.56M | 0.16% |
| 2 | iShares MSCI Japan Small-Cap ETF SCJ | 0.15% | 396.3K | 0.50% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.15% | 865.1K | 0.58% |
| 4 | Pacer Developed Markets International Cash Cows 100 ETF ICOW | 0.14% | 2.38M | 0.65% |
| 5 | Vanguard Global Momentum Factor ETF VMO.TO | 0.09% | 342.2K | 0.38% |
| 6 | Xtrackers Nikkei 225 UCITS ETF 2D EUR Hedged XDJE.DE | 0.07% | 2.33M | 0.19% |
| 7 | Xtrackers Nikkei 225 UCITS ETF 1D XDJP.L | 0.07% | 2.33M | 0.09% |
| 8 | iShares Nikkei 225 UCITS ETF (DE) EXX7.DE | 0.07% | 222.4K | 0.51% |
| 9 | iShares Nikkei 225 UCITS ETF CNKY.L | 0.07% | 465.3K | 0.48% |
| 10 | iShares Nikkei 225 UCITS ETF 1329.T | 0.07% | 8.95M | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Toru Kimura | Representative Director, President & Chief Executive Officer | 101M | male |
| Isao Shimizu | Exec. Off.,SVP, Dep. Head of R&D Div. & Corp. Reg.Comp & Quality Assurace. Div. | — | male |
| Katsuhiko Nishida | EO, SVP of S&M & Head of Japan BU Deputy | — | — |
| Kenji Ueno | Executive Officer, Senior Vice President and Deputy Head of Research and Development Division (CMC) | — | male |
| Kimihiro Mizuno | Executive Officer Legal & Compliance and Intellectual Property | — | male |
| Koichi Kozuki | E.O. of Corp. Reg. Comp., Bus Dev mgmt & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div & Dp. Hd of Jap. Bus. | — | male |
| Koji Yamazaki | Exec. Off. of Sales & Mark. Div., SVP, Hd. of Sales & Mark. Div. Dep. Hd. of Japan Bus. Unit | — | — |
| Motoyuki Sakai | EVP of Glob. C.ST., Glob. Fin. Admin. Ext. Aff., Corp. Gov. Corp. Com, IT Mngt., DA & Rep. Dir | — | male |
| Shunji Kobayashi | Executive Officer of Human Resources | — | — |
| Tsutomu Nakagawa | Managing Executive Officer & Director | — | — |
| Hideyuki Harada | Mng. Exe. Off. of Supply Chain Div., SVP, Hd. of Supply Chain Div. & Hd. of Japan Bus. Unit | — | male |
| Yumi Sato | Managing Exe. Officer of Research & Dev. Div. Senior Vice President and Head of Research & Development Division | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4506.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
